Role of TPE in ACLF study details

TITLE

Role of Therapeutic plasma exchange (TPE) in acute on chronic liver failure (ACLF) – a prospective multicentre study

AIM

To study the impact of TPE on mortality in patients with ACLF of all etiologies

OBJECTIVES

- To assess efficacy and safety of TPE in patients with ACLF of all etiologies.
- To assess 7 days, 28 days, 3 months ,6 months survival in patients with ACLF undergoing PLEX.
- To identify the subset of patients who will benefit from TPE as a bridge to transplant or as a tool to improve transplant free survival.

INCLUSION CRITERIA

Acute on chronic liver failure diagnosed based on APASL or EASL definition

EXCLUSION CRITERIA

Acute liver failure

Cholestatic liver diseases

HCC

Cardiomyopathy

Chronic kidney disease

COPD/ severe pulmonary diseases

METHODS

Patients diagnosed to have ACLF of any etiology based on either APASL definition or EASL

definition will be included for the study. Patients who meet exclusion criteria will be

excluded. Nature of disease and prognosis, need for liver transplant as the best available treatment option will be explained to patient's relatives. If they are not willing for transplant or if transplant is not feasible immediately due to various reasons, then option of PLEX as a bridge to transplant or as a trial of additional treatment measure apart from standard medical care will be explained. Patient will be included for the study if the patient consent is obtained.

Standard medical therapy like antiviral therapy, liver supportive measures, organ supportive measures like hemodialysis, inotropes or mechanical ventilation as per standard ICU care will be provided.

Baseline demographic data, details of ACLF like cause of acute insult, cause of chronic liver disease, severity of ACLF as per various standard scores will be recorded. PLEX will be done as per the institution's protocol . Number of sessions , method of exchange , volume of exchange and replacement fluid details will be recorded . Any adverse events will be recorded. Additional information like line access, steroid use , presence of sepsis will be noted.

Further course of patient's illness will be analysed in terms of change in severity of ACLF, time to transplant, time to mortality, transplant free survival rate.